CCR5 Co-receptor Antagonist global drug patents, pharmaceutical manufacturers and generics

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	SELZENTRY	maraviroc	TABLET;ORAL	022128-003	Nov 4, 2016		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Viiv Hlthcare	SELZENTRY	maraviroc	TABLET;ORAL	022128-004	Nov 4, 2016		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Viiv Hlthcare	SELZENTRY	maraviroc	TABLET;ORAL	022128-001	Aug 6, 2007	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 7, 2026

CCR5 co-receptor antagonist market dynamics and patent landscape (strategic overview across drug candidates)

CCR5 co-receptor antagonists target HIV-1 entry by blocking CCR5, plus expanded indications in inflammation and neuropsychiatric disease have been pursued across the class. The patent landscape is concentrated around lead agents (notably maraviroc) and around next-generation CCR5 blockers and combinations, with most commercial revenue exposure tied to branded HIV therapy products where exclusivity and patent estates govern generic and new-label competition. Market dynamics hinge on HIV guideline placement (treatment-experienced versus naïve use), resistance patterns, payer formularies, and manufacturing/therapeutic equivalency barriers. Patent risk for challengers is driven by method-of-use coverage, formulation/process patents, and enforceable Orange Book listings tied to specific dosage forms and strengths.

Which CCR5 antagonists generate revenue today, and how do their market dynamics differ?

The commercial CCR5 antagonist footprint is still dominated by maraviroc for HIV-1 infection, with other CCR5 blockers largely in lower-commercialization modes or earlier-stage development depending on jurisdiction and trial outcomes.

Key revenue-driving CCR5 antagonists

Maraviroc (HIV-1 entry inhibitor; CCR5 antagonist)
Other CCR5 antagonists: class members have appeared across development cycles, including antagonists intended to improve potency, dosing convenience, safety, or resistance profile. In practice, few have matched the sustained HIV commercial adoption of maraviroc.

Market dynamics drivers by segment (HIV)

Guideline positioning and sequencing
- CCR5 antagonists are typically used in regimens where viral tropism is CCR5-tropic (or where results support CCR5 pathway dependence). This reduces addressable patient populations relative to agents that do not require tropism screening.
Resistance and treatment-experience
- CCR5 antagonists face resistance through viral envelope changes and tropism shifts, which impacts durability and switching patterns.
Formulary and payer
- Branded pricing power declines as alternative NRTI backbones and INSTI-based regimens expand. CCR5 antagonists often remain in formularies for specific subgroups where they fit clinically.
Companion diagnostics
- Tropism testing requirements shape prescribing behavior and adherence to labeled indications.
Generic entry and lifecycle
- When maraviroc patent families weaken, generic erosion and reimbursement rationalization materially change net pricing and market share.

Market dynamics drivers outside HIV

Expanded indications (inflammation, neuropsychiatric, fibrotic and other areas) have seen variable translational outcomes. Where phase programs failed, patent filing activity often shifted into composition-of-matter or method-of-use survival strategies around biomarkers, patient subsets, or combination regimens.

What patents protect maraviroc (CCR5 antagonist) and how broad is the estate?

Maraviroc’s patent landscape is the class anchor in enforceable IP tied to the branded HIV product. The estate typically spans:

Composition of matter for the active
Pharmaceutical compositions (tablet/capsule, film coating, excipients)
Formulation improvements (bioavailability, dissolution, stability)
Manufacturing processes (crystallization, intermediates, purification)
Method-of-use claims (treatment of HIV, treatment regimens, tropism-defined subpopulations)

Where strong leverage typically concentrates

In CCR5 antagonist enforcement, the highest leverage usually sits in:

Product-specific Orange Book listings (strength, dosage form, formulation)
Use claims that map to the most-reimbursed labeled regimens
Process patents that create manufacturing/IP barriers

Typical patent-family structure for a mature CCR5 brand

Active ingredient family: filed years before commercial launch, often with expiration anchored by earliest effective filing date plus statutory term adjustments.
Secondary families: cover improvements and lifecycle management, with later filing dates extending enforceability in specific dosage forms or manufacturing embodiments.
Method-of-use: claims tied to clinical subsets (for example, CCR5-tropic patients) can remain enforceable even as composition claims expire.

What is the Orange Book status of maraviroc and which listed patents drive exclusivity?

Orange Book status and listed patent numbers determine Paragraph IV exposure for each dosage form/strength. For CCR5 antagonists, the key business question is which patents are listed for:

the reference listed drug (RLD),
specific strengths and dosage forms, and
which patents have unexpired status at the time of potential generic submission.

What to look for in Orange Book listings for CCR5 antagonists

Drug substance patents: composition-of-matter for the active
Drug product patents: formulation, dosage form, release characteristics
Method-of-use patents: treatment claims that can still control despite generic drug substance equivalence

When does maraviroc lose exclusivity and what are the key expiration dates?

For a mature CCR5 antagonist like maraviroc, exclusivity loss is usually a function of:

patent expiration across the controlling families,
regulatory exclusivities tied to supplemental applications (if any), and
orphan/pediatric exclusivity in other therapeutic contexts (less likely for HIV where standard exclusivity dominates).

Timeline mechanics for challenger risk

First generic launch risk typically aligns with:
- expiration of the last listed patent family that blocks approved ANDA products, or
- successful resolution of litigation (settlement) that permits earlier launch.
Patent estate strength is assessed by:
- number of listed patents expiring in sequence,
- whether method-of-use listings remain, and
- whether formulation/process patents are separately enforceable.

Which CCR5 co-receptor antagonist patents are most vulnerable to Paragraph IV ANDA challenges?

Paragraph IV challenges typically target the patents most likely to be contestable:

older composition-of-matter families with weaker claim scope,
patents with design-arounds (reformulation, alternative manufacturing route),
patents that appear narrow in claim construction or lack support across possible equivalents.

Typical claimant strategies in CCR5 antagonist cases

Challenge one or more Orange Book-listed patents while agreeing to certify non-infringement or invalidity for specific claims.
Use generic development and bioequivalence to avoid product-level infringement.
Design manufacturing to avoid process claim elements where process patents control.

Litigation outcomes that change market entry windows

For CCR5 antagonists, commercial entry timing usually depends less on abstract patent invalidity theories and more on:

court claim construction for method-of-use,
settlement terms that cap launch dates and distribute generic market access.

What patent litigation affects CCR5 antagonist generic entry?

CCR5 antagonist generic entry risk is driven by:

whether the RLD brand has asserted method-of-use and formulation claims in addition to drug substance,
how courts interpret claim scope against generic labeling and claimed regimens, and
whether settlements include automatic stay triggers tied to entry dates.

How litigation posture changes the commercial outcome

If litigation focuses on method-of-use, generics can face labeling or carve-out constraints even if the generic drug is approved.
If formulation/process patents are dominant, generics can face supply-side delays due to redesign and revalidation requirements.

How do settlement agreements and FDA approval timing interact for CCR5 antagonists?

For mature brands, settlements often function as:

a de facto license permitting entry at a defined date,
an agreement defining permitted claims and labeling positions,
sometimes a “no earlier than” market access schedule aligned with the last blocking patent or agreed launch.

Business impact channels

Cash-flow timing: a settlement advances or preserves revenue by shifting launch by months to years.
Exclusivity stacking: settlements can align with regulatory exclusivity windows to extend net protection.
Certainty of entry: payers and providers plan formularies based on expected availability dates.

What biosimilar risk exists for CCR5 antagonists, and how does it differ from small-molecule competition?

CCR5 antagonists in this class are primarily small molecules, not biologics. That means “biosimilar risk” is typically not applicable unless a CCR5-targeting therapy uses a biologic modality in a separate pipeline.

Practical implication

Competition risk is mainly from generics (ANDAs) and possibly authorized generics.
Patent estate analysis focuses on small-molecule composition, formulation, and method-of-use, not biologic comparability.

What formulations are protected for CCR5 antagonists, and what are common design-around routes?

Formulation patents are common in mature oral therapies, because they can protect:

dissolution rates,
crystallinity forms,
excipient systems that control stability,
coatings and tablet/capsule technology.

Typical protected formulation categories

Film-coated tablets/capsules with specific excipient ratios
Bioavailability-enhanced compositions (where permitted by label and evidence)
Controlled-release variants (if any exist for the brand)
Stable polymorph or salt forms in solid-state embodiments

Design-around paths for challengers

Switch excipient system while maintaining bioequivalence
Use alternative particle size distributions
Reformulate to avoid specific coated compositions or dissolution profile claim elements
Change manufacturing route to avoid crystallization/process claim elements

How do method-of-use patents for CCR5 antagonists shape generic labeling and infringement?

Method-of-use patents can force generics into:

label carve-outs for the protected regimen,
or certifications that limit launch timing until dispute resolution.

Common method-of-use claim themes

Treating HIV-1 infection by administering a CCR5 antagonist under conditions consistent with tropism testing.
Treating specific populations (treatment-experienced, prior regimen failures, or CCR5-tropic subset).
Combination regimens where claim language ties to co-administered agents.

Labeling as an enforcement lever

Even when a generic can be pharmaceutically equivalent, it can still trigger infringement if the label induces the protected use.
Courts often rely on the “what the label authorizes” framing for method-of-use infringement.

Which CCR5 antagonist companies hold the strongest IP positions, and what is the competitive landscape?

Competitive landscape analysis for CCR5 antagonists focuses on:

branded originator patent holders,
generic entrants and their Paragraph IV strategy history,
licensees with authorized generic or co-development roles.

IP position drivers

number of listed patents per dosage form
breadth and enforceability of method-of-use claims
strength of formulation/process protection
whether litigation has produced claim narrowing or invalidations

How strong is the patent estate for the CCR5 antagonist class, and where are the expiration clusters?

The class strength is usually “high” for the lead brand(s) and “low-to-mixed” for other members. In a mature small-molecule class, expiration often clusters:

drug substance patents expire first,
then formulation/process and method-of-use families define the remaining entry window.

Portfolio mapping framework for decision-makers

Identify the last expiring Orange Book-listed patent for each dosage form/strength.
Track additional patent families that do not appear in Orange Book but may still be enforceable (for example, unlisted secondary patents in district court).
Identify whether the estate is “thin” in a specific region: global enforcement can differ.

What generic entry risks exist for CCR5 antagonists by jurisdiction and dosage form?

Jurisdictional differences matter because:

patent term adjustments and patent linkage status differ,
litigation venue and enforcement efficiency vary,
ANDA linkage applies for FDA Orange Book, while other jurisdictions use different infringement/marketing authorizations.

Dosage form risk

Different strengths can have different listed patents.
A challenger may pursue a strength where the last blocking patent expires later, or where entry is strategically easier.

Commercial risk profiles

“High risk” for challengers when method-of-use and multiple formulation/process patents are listed and actively litigated.
“Moderate risk” when only drug product or limited formulation patents remain.
“Lower risk” when only older composition families remain and are not dominant in litigation.

How does maraviroc compare with other CCR5 co-receptor antagonists on IP strength and time-to-generic?

A class-level comparison typically shows:

Maraviroc: largest and most mature patent estate with long tail method-of-use and product/formulation listings.
Other CCR5 antagonists: smaller footprints, often with fewer enforceable listings tied to commercially scaled branded products.

Comparative factors that determine time-to-generic

whether each competitor has an Orange Book linkage footprint (for US)
how many product strengths exist
whether there are lifecycle patents on formulation/process
litigation history and settlement schedules

Key tables: patent estate, exclusivity, and generic entry readiness

Table 1: Patent estate components to map for CCR5 antagonists

Estate segment	What it covers	Why it blocks generics	Typical enforcement lever
Drug substance (composition)	Active ingredient structure	ANDA must avoid infringement or wait	Claim construction on core moiety
Drug product (formulation)	Dosage form, excipients, coating	Even bioequivalent products may infringe	Dissolution/excipient system claim mapping
Method-of-use	Treatment regimens with CCR5 context	Labeling triggers induced infringement	Label carve-out litigation
Manufacturing/process	Crystallization/purification route	Supply-side infringement risk	Proof of process equivalence
Regulatory exclusivity	Supplemental approvals, exclusivity grants	Adds time beyond patents	Stacking with last blocking patent

Table 2: Generic entry decision points (checklist)

Decision gate	Evidence to anchor	Business impact
Last Orange Book blocking patent by strength	Listed patent expiry dates	Determines “no earlier than” launch date
Litigation stay/settlement schedule	Court dockets and settlement terms	Overrides theoretical expiry timing
Label infringement risk (method-of-use)	Label vs claim scope	Can delay launch despite approval
Formulation/process infringement risk	Generic manufacturing route	Can force redesign and revalidation

Key Takeaways

CCR5 antagonist market dynamics are still dominated by maraviroc in HIV, where clinical positioning and resistance patterns narrow addressable populations relative to broader-spectrum regimens.
The patent landscape is concentrated in Orange Book-listed protections and long-tail method-of-use and formulation/process families for the lead product.
Generic entry timing is determined less by generic pharmacokinetics and more by last blocking listed patents, method-of-use labeling enforcement, and settlement-driven “no earlier than” schedules.
Biosimilar risk is generally not applicable for small-molecule CCR5 antagonists, shifting competition risk to ANDAs and formulation/process design-arounds.

FAQs

1) What Orange Book patents matter most for CCR5 antagonist generic launch timing?
Answer: The last expiring listed patents per dosage form and strength, especially method-of-use and drug product/formulation listings that align with labeled regimens.

2) Can a generic CCR5 antagonist launch with a modified label to avoid method-of-use infringement?
Answer: It depends on claim construction and whether label carve-outs still avoid infringement under induced infringement theories tied to protected treatment regimens.

3) Which patent families most commonly survive longer in CCR5 antagonist lifecycles?
Answer: Secondary formulation and manufacturing/process families plus late-filed method-of-use claims tied to patient subsets or regimen details.

4) How do resistance and tropism testing affect CCR5 antagonist commercial durability?
Answer: They reduce long-term switching durability and shape prescribing, which affects payer mix and the economic value of delaying generic entry.

5) What settlement patterns are typical in CCR5 antagonist ANDA disputes?
Answer: Settlements frequently establish an agreed launch date linked to remaining blocking patents, with label and enforcement covenants controlling the competitive path.

References (APA)

No sources were cited in the provided analysis.